Genelux (GNLX) insider option repricing lowers exercise prices to $3.33

Rhea-AI Filing Summary

Genelux Corporation director and Chief Technical Officer Joseph Cappello reported a series of option transactions dated 09/01/2025. The filing shows a one-time reduction of option exercise prices effective that date: several stock options previously priced at $6.00 and $22.40 were reduced to an exercise price of $3.33, described as the issuer's common stock price on September 1, 2025. The filing records both dispositions (D) of the higher-priced options and acquisitions (A) of replacement options at $3.33, with no changes to expiration dates or vesting schedules. The filing notes that the shares subject to these options are fully vested for some grants and specifies vesting terms for others.

Positive

• Exercise prices reduced to $3.33 effective September 1, 2025, as explicitly disclosed
• No change to expiration dates or vesting schedules for the affected options, per the filing
• Some option shares are fully vested, as stated in the explanation

Negative

• Dispositions recorded of previously issued options with $6.00 and $22.40 exercise prices (reported as D in the table)
• Large number of options affected (multiple grants totaling over 179,000 underlying shares listed in the table)

Insights

Securities Analyst

TL;DR: Insider option exercise prices were lowered to $3.33 on 09/01/2025 with unchanged expirations and vesting; reported as dispositions and acquisitions.

The reported Form 4 documents a one-time adjustment that reduces the exercise price of multiple option grants to $3.33, the stated market price on September 1, 2025. The filing shows parallel disposition (D) of options with prior exercise prices ($6.00 and $22.40) and acquisition (A) of replacement options at $3.33, preserving original expiration dates and vesting schedules. For investors, the item is a clearly disclosed insider compensation modification rather than a new cash transaction; the filing explicitly indicates which options remain beneficially owned following the transactions.

Corporate Governance Expert

TL;DR: Option repricing was executed on a one-time basis affecting a senior officer; vesting and expirations unchanged per the filing.

The Form 4 provides explicit detail that exercise prices for multiple option grants held by the reporting person were reduced to the issuer's $3.33 common-stock price as of September 1, 2025. The filing clarifies there was no change to expiration dates or vesting schedules and that some option shares are fully vested. The disclosure is concise and compliant with Section 16 reporting requirements, documenting both the dispositions of the higher-priced awards and the acquisitions of the repriced awards.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cappello Joseph

(Last) (First) (Middle)

C/O GENELUX CORPORATION

2625 TOWNSGATE ROAD, SUITE 230

(Street)

WESTLAKE VILLAGE CA 91361

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GENELUX Corp [ GNLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technical Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6	09/01/2025		D			16,666	(1)	12/30/2026	Common stock	16,666	(2)	0	D
Stock Option (Right to Buy)	$3.33	09/01/2025		A		16,666		(1)	12/30/2026	Common stock	16,666	(2)	16,666	D
Stock Option (Right to Buy)	$6	09/01/2025		D			80,000	(1)	09/12/2027	Common stock	80,000	(2)	0	D
Stock Option (Right to Buy)	$3.33	09/01/2025		A		80,000		(1)	09/12/2027	Common stock	80,000	(2)	80,000	D
Stock Option (Right to Buy)	$6	09/01/2025		D			13,333	(1)	09/23/2030	Common stock	13,333	(2)	0	D
Stock Option (Right to Buy)	$3.33	09/01/2025		A		13,333		(1)	09/23/2030	Common stock	13,333	(2)	13,333	D
Stock Option (Right to Buy)	$22.4	09/01/2025		D			65,000	(3)	09/10/2033	Common stock	65,000	(2)	0	D
Stock Option (Right to Buy)	$3.33	09/01/2025		A		65,000		(3)	09/10/2033	Common stock	65,000	(2)	65,000	D

Explanation of Responses:

1. The shares subject to these options are fully vested.

2. The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options.

3. The shares subject to the option vest as follows: 25% on September 11, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.

	/s/ Thomas Zindrick, J.D. Attorney-in-Fact	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What change to option exercise prices did the GNLX Form 4 report?

The filing states a one-time reduction of option exercise prices to $3.33 effective September 1, 2025.

Which reporting person filed the Form 4 for GNLX?

The reporting person is Joseph Cappello, identified as Director and Chief Technical Officer.

Did the repricing change option expiration dates or vesting?

No. The filing explicitly says there is no change to expiration dates or the vesting schedule.

What prior exercise prices were replaced according to the filing?

The table shows dispositions of options previously exercisable at $6.00 and $22.40, which were replaced with options at $3.33.

How many underlying shares are shown for the repriced grants?

The table shows repriced option amounts of 16,666, 80,000, 13,333, and 65,000 shares for the listed grants.